Replimune Group, Inc. (NASDAQ: REPL) is a Healthcare company (Biotechnology) with a market capitalization of $1.9B. The Maz Rating grades it against the other companies in its sector.
Replimune Group, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $19.69, Replimune Group, Inc. trades at 10.1x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -157.8%, return on invested capital of -80.9% and a free cash flow yield of -13.2%. On the balance sheet: a debt-to-equity ratio of 0.62 and a current ratio of 7.11. Over the past 52 weeks the share price ranged from $1.50 to $23.54, with a beta of 0.93.
Replimune Group, Inc. does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 11 Buy, 3 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Replimune Group, Inc. (REPL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 6.66% / 30% · (Cash+Inv) / Mkt Cap (36m) 20.7% / 30% · Interest income / Revenue 188000000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 6.66% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 20.5% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 188000000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 6.66% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 20.5% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 188000000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 24.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 80.6% / 33.33% · Receivables / Avg Assets (4Q) 0.35% / 33.33% · Interest income / Revenue 188000000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 26.7% / 33.33% · (Cash+ST Inv) / Total Assets 82.3% / 33.33% · (Cash+Recv) / Total Assets 82.3% / 33.33% · Interest income / Revenue 188000000.0% / 5% | Fail |
No. As of September 2026, Replimune Group, Inc. (REPL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Replimune Group, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 188000000.0% of each dividend: Replimune Group, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q2 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.